Guide Use of Tocilizumab for COVID-19 Based on New Data

You'll hear renewed interest in tocilizumab for COVID-19...based on new data suggesting it reduces mortality in some patients.

IL-6 inhibitors, such as tocilizumab (Actemra), sparked early interest in COVID-19 to block cytokines and reduce inflammation.

But trials haven't consistently demonstrated a benefit.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote